Observation of CBD therapy inpatients with intractable epilepsy

Observation of CBD therapy inpatients with intractable epilepsy - CBD-ET

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

DRKS

Registry ID

DRKS00013177

Enrollment

Registered

2019-06-25

Start date

2017-12-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G40

Interventions

Group 1: Cannabidiol oily solution start 5mg/kg/d, up titrated according to tolerance to maximum of 50mg/kg/d.

Eligibility

Sex/Gender

All

Age

1 Months to No maximum

Inclusion criteria

Inclusion criteria: pharmacoresistant epilepsy, treatment with at least one anticonvulsive drug, CBD therapy

Exclusion criteria

Exclusion criteria: cannabinoid treatment within 4 weeks of screening, pregnancy, instable hepatic or renal disease

Design outcomes

Primary

Measure	Time frame
Percentage change of seizure frequency per month of motor seizures after 3 months of CBD compared to 1 month of baseline	—

Secondary

Measure	Time frame
Percentage change of seizure frequency per month of all seizures after 3 months of CBD compared to 1 month of baseline plus change of motor and all seizures per month after 6,12,18,24,36 months of treatment compared to baseline	—

Countries

Germany

Contacts

Public ContactKerstin Alexandra Klotz

Abteilung für Epileptologie des Universitätsklinikums Freiburg

kerstin.alexandra.klotz@uniklinik-freiburg.de+4976127043520

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 20, 2026